ADAR1 Capital Management LLC Has $463,000 Stock Position in Insmed, Inc. $INSM

Key Points

• ADAR1 Capital Management LLC significantly reduced its holdings in Insmed, Inc. by 72.4%, selling 15,900 shares and leaving it with 6,074 shares worth approximately $463,000.
• Several large investors have adjusted their stakes in Insmed, including a $975,000 investment from the Teachers Retirement System of the State of Kentucky and a 47.1% increase in shares held by OneDigital Investment Advisors LLC.
• Analysts are optimistic about Insmed, with sixteen research analysts giving it a Buy rating and multiple firms raising their price targets, including Jefferies Financial Group, which increased its target from $129.00 to $148.00.

ADAR1 Capital Management LLC trimmed its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 72.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,074 shares of the biopharmaceutical company's stock after selling 15,900 shares during the period. ADAR1 Capital Management LLC's holdings in Insmed were worth $463,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Cullen Frost Bankers Inc. lifted its holdings in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares during the last quarter. Elequin Capital LP purchased a new stake in shares of Insmed during the fourth quarter valued at $28,000. NBC Securities Inc. purchased a new stake in shares of Insmed during the first quarter valued at $49,000. Versant Capital Management Inc lifted its holdings in shares of Insmed by 546.3% during the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 590 shares during the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of Insmed by 60.0% during the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after purchasing an additional 325 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on INSM shares. Morgan Stanley increased their price objective on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Truist Financial increased their price objective on Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. HC Wainwright increased their price objective on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Wells Fargo & Company increased their price objective on Insmed from $140.00 to $171.00 and gave the stock an "overweight" rating in a research note on Wednesday. Finally, Leerink Partners increased their price objective on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 10th. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $134.79.

Insmed Stock Up 1.8%

INSM stock traded up $2.57 during mid-day trading on Friday, hitting $145.10. The stock had a trading volume of 2,532,328 shares, compared to its average volume of 2,914,153. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $146.84. The company has a fifty day moving average of $114.64 and a 200 day moving average of $89.66. The stock has a market capitalization of $30.67 billion, a price-to-earnings ratio of -25.41 and a beta of 0.97.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period in the previous year, the company earned ($1.94) earnings per share. The business's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the transaction, the insider owned 89,407 shares of the company's stock, valued at approximately $8,352,401.94. This represents a 52.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Michael Alexander Smith sold 24,272 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $143.89, for a total value of $3,492,498.08. Following the transaction, the insider directly owned 54,902 shares in the company, valued at approximately $7,899,848.78. This represents a 30.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 535,320 shares of company stock worth $54,581,793 in the last 90 days. Company insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.